Could a statin tame fatty liver disease? new trial seeks answers
NCT ID NCT04679376
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether atorvastatin (Lipitor), a widely used cholesterol medication, can safely improve liver damage in people with NASH, a serious fatty liver disease. About 70 adults with confirmed NASH and liver scarring will receive either the drug or a placebo. The goal is to see if the drug can reduce liver inflammation and scarring without making the disease worse.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASH - NONALCOHOLIC STEATOHEPATITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Duke University Medical Center
Durham, North Carolina, 27710, United States
-
Mayo Clinic Minnesota
Rochester, Minnesota, 55905, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could estrogen patch reverse liver damage in postmenopausal women?
- Experimental drug aims to reverse liver scarring in NASH cirrhosis
- New drug HPG1860 shows promise in reducing liver fat in NASH patients
- Hope for NASH: new pill aims to reverse liver damage and prevent cirrhosis
- Sleeve gastrectomy vs. lifestyle: which tames fatty liver disease?
- Can a keto diet help obese patients with advanced liver disease?